Ferring expands HEART program for cash-paying fertility patients

January 4, 2008

Ferring fertility program expanded

Ferring Pharmaceuticals has announced an expansion of its Helping Expand Access to Reproductive Therapy (HEART) program, a cost-savings plan for patients considering fertility treatments. Under the new plan, women who are prescribed urofollitropin for injection (Bravelle) and progesterone vaginal insert, 100 mg (Endometrin), will be eligible to receive the drugs at a discounted price. The program allows patients to receive five vials of Bravelle at no cost after they have purchased 15 or more vials of the hormone — a $300 value, along with a free box of Endometrin (containing 21 inserts) — a $100 value. To be eligible, patients must be cash-paying customers and must take the prescriptions to a participating pharmacy. More information can be found at